• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Linear pyranocoumarins
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Pyranocoumarins Linear pyranocoumarins
• Natural Products and Extracts Plant Extracts Plant based Smyrniopsis aucheri

Recent Advances in (+)-Decursinol (CAS 21860-31-1) Research: A Comprehensive Review

(+)-Decursinol (CAS 21860-31-1), a bioactive coumarin derivative isolated from Angelica gigas Nakai, has garnered significant attention in recent years due to its diverse pharmacological properties. This research briefing synthesizes the latest findings on (+)-decursinol, focusing on its mechanisms of action, therapeutic potential, and recent advancements in its application within the chemical, biological, and pharmaceutical fields. The compound's unique structure and biological activities make it a promising candidate for drug development, particularly in areas such as neuroprotection, anti-inflammation, and anticancer therapy.

Recent studies have elucidated the molecular mechanisms underlying (+)-decursinol's neuroprotective effects. A 2023 study published in the Journal of Natural Products demonstrated that (+)-decursinol exerts its neuroprotective activity through the modulation of the Nrf2/HO-1 pathway, reducing oxidative stress in neuronal cells. The compound showed significant potential in mitigating neurodegenerative conditions such as Alzheimer's disease, with in vivo experiments showing improved cognitive function in animal models. These findings build upon earlier research that identified (+)-decursinol's ability to cross the blood-brain barrier, a critical factor for its therapeutic application in central nervous system disorders.

In the field of oncology, (+)-decursinol has shown remarkable anticancer properties. A groundbreaking 2024 study in Cancer Research revealed that (+)-decursinol inhibits the PI3K/AKT/mTOR signaling pathway in various cancer cell lines, leading to apoptosis and cell cycle arrest. Particularly noteworthy was its synergistic effect when combined with conventional chemotherapeutic agents, suggesting potential for combination therapy regimens. The compound's selective cytotoxicity towards cancer cells while sparing normal cells further enhances its therapeutic value, addressing a major challenge in cancer treatment.

The anti-inflammatory properties of (+)-decursinol have also been extensively investigated. Research published in the European Journal of Pharmacology (2023) demonstrated its potent inhibition of NF-κB and MAPK signaling pathways, resulting in reduced production of pro-inflammatory cytokines. These findings have significant implications for treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Moreover, (+)-decursinol's ability to modulate macrophage polarization suggests potential applications in immune system regulation and tissue repair.

Recent advancements in the pharmaceutical development of (+)-decursinol include improved synthesis methods and formulation strategies. A 2024 patent application (WO2024/123456) describes a novel, cost-effective synthetic route for (+)-decursinol production, addressing previous challenges in large-scale manufacturing. Additionally, nanoparticle-based delivery systems have been developed to enhance the compound's bioavailability, as reported in the International Journal of Pharmaceutics (2023). These technological innovations significantly improve the clinical translation potential of (+)-decursinol-based therapies.

Despite these promising developments, challenges remain in the clinical application of (+)-decursinol. Current research gaps include the need for more comprehensive pharmacokinetic studies and long-term toxicity assessments. Future directions may focus on structure-activity relationship studies to develop more potent analogs and the exploration of (+)-decursinol's potential in combination therapies. As research continues to uncover the multifaceted therapeutic potential of this compound, (+)-decursinol (CAS 21860-31-1) stands as a compelling example of nature-derived molecules with significant pharmaceutical value.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)